603 related articles for article (PubMed ID: 19302416)
1. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
Picker SM; Oustianskaia L; Schneider V; Gathof BS
Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
[TBL] [Abstract][Full Text] [Related]
2. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
Picker SM; Steisel A; Gathof BS
Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
[TBL] [Abstract][Full Text] [Related]
3. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
Picker SM; Steisel A; Gathof BS
Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
[TBL] [Abstract][Full Text] [Related]
4. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
Picker SM; Tauszig ME; Gathof BS
Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
[TBL] [Abstract][Full Text] [Related]
5. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies.
Picker SM; Schneider V; Oustianskaia L; Gathof BS
Transfusion; 2009 Nov; 49(11):2311-8. PubMed ID: 19624608
[TBL] [Abstract][Full Text] [Related]
6. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
Picker SM; Schneider V; Gathof BS
Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
[TBL] [Abstract][Full Text] [Related]
8. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
9. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
Tauszig ME; Picker SM; Gathof BS
Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
[TBL] [Abstract][Full Text] [Related]
10. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction.
AuBuchon JP; Herschel L; Roger J; Taylor H; Whitley P; Li J; Edrich R; Goodrich RP
Transfusion; 2005 Aug; 45(8):1335-41. PubMed ID: 16078923
[TBL] [Abstract][Full Text] [Related]
13. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
[TBL] [Abstract][Full Text] [Related]
15. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days.
Moog R; Fröhlich A; Mayaudon V; Lin L
J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347
[TBL] [Abstract][Full Text] [Related]
17. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
Lozano M; Galan A; Mazzara R; Corash L; Escolar G
Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage.
Li J; Goodrich L; Hansen E; Edrich R; Gampp D; Goodrich RP
Transfusion; 2005 Nov; 45(11):1750-8. PubMed ID: 16271100
[TBL] [Abstract][Full Text] [Related]
19. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation on collagen via integrin αIIbβ3 activation.
Terada C; Mori J; Okazaki H; Satake M; Tadokoro K
Transfusion; 2014 Jul; 54(7):1808-16. PubMed ID: 24506417
[TBL] [Abstract][Full Text] [Related]
20. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
